• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ProSolus invests in manufacturing capacity for transdermal drug delivery tech

April 26, 2017 By Sarah Faulkner

Transdermal patch production lineMission Pharmacal subsidiary ProSolus Inc. said this week that it expanded its manufacturing capabilities and commercialization efforts for transdermal drug delivery technologies.

The Miami-based company, which develops and manufactures transdermal and trans-mucosal drug delivery products, installed a 2nd transdermal production facility in Boerne, Texas. The new location has a larger production line than the Miami site, according to ProSolus, and the 2 sites have a combined annual capacity of more than 100 million patches.

“For us, it’s all about the convenience and wear-ability of patches – creating more desirable, smaller sizes that stay in place while working effectively,” chief operating officer & chief scientific officer Juan Mantelle said in prepared remarks. “We are consistently searching for new and better ways to bring transdermal products to market.”

Transdermal patches deliver medication through skin and into the bloodstream. Transdermal systems tend to use lower doses of active ingredients, ProSolus said, and therefore can lessen harsh side effects more efficiently than other drug delivery techniques.

The company also launched a new commercial team, lead by Jim Self, to seek out partnerships between ProSolus and companies in the pharmaceutical industry.

“We look forward to increased partnerships with a wide array of pharmaceutical companies looking to commercialize products utilizing leading transdermal patch technology,” Self said. “Together we will be able to efficiently develop what are normally considered high-barrier-to-entry solutions and expand the overall transdermal market space, ultimately improving the care and treatment of patients.”

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Mission Pharmacal, ProSolus

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS